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The recent discovery of a plasmid-mediated mcr-1 gene encoding for colistin resistance in 
Escherichia coli and Klebsiella pneumoniae from animals, food, and humans in China [1] has 
initiated the global research of this plasmid in different hosts and different Gram-negative 
bacteria (GNB) [2].  
The mcr-1 gene has been identified in five continents from bacteria isolated from several origins, 
including animals, food, the environment, and humans [3, 4]. Several studies, conducted mostly 
in animals, have reported the identification of the mcr-1 gene among Extended-Spectrum β-
Lactamases (ESBL) producing E. coli [5-8]. In a retrospective study, Shen and collaborators 
reported the identification of the mcr-1 gene in three E. coli strains from chickens in China 
isolated in the 1980s [9]. To the best of our knowledge, this is the oldest identification of the mcr-
1 gene reported in scientific literature.  
Is it possible there is a simultaneous coexistence between ESBL, carbapenemase enzymes, and 
the mcr-1 gene? 
Historical events concerning the discovery and emergence of plasmid-mediated colistin-resistant 
bacteria as well as ESBL and carbapenemase genes are traced in Figure 1. Colistin was 
discovered in 1949 and became available for clinical use in the 1960s for the treatment of GNB 
[10]. Colistin use was very restricted between 1970 and the late 1990s in humans due to its 
reported nephrotoxicity and the development of less-toxic antimicrobial agents. However no 
restriction was reported on colistin use in veterinary medicine during this period [3].  
Extended-spectrum (or third-generation) cephalosporins (e.g., cefotaxime, ceftriaxone, 
ceftazidime) were introduced into clinical use in the early 1980s [11]. These β-lactam antibiotics 
were regarded as a major advance in the treatment of infection caused by β-lactamase-producing 
bacteria [12]. However, the emergence of resistance against these antibiotics was observed, with 
the first report on plasmid-encoded β-lactamase enzymes capable of hydrolyzing the extended-
	 3	
spectrum cephalosporins in K. pneumoniae published in 1983 [11]. This seems to correspond to 
the first identification of the mcr-1 gene in E. coli, according to Shen and collaborators [9], which 
indicates a temporal concurrence between the first identification of ESBL enzymes and that of 
the mcr-1 gene.  
In 1985, the first carbapenems (imipenem) were marketed for the treatment of infections caused 
by Enterobacteriaceae, particularly those producing ESBLs [13, 14]. After a decade of practical 
use of carbapenems, a strain carrying the plasmid K. pneumoniae carbapenemase (KPC-1) was 
first observed in North Carolina in 1996 before progressively appearing worldwide [15].  
The presence of ESBL and carbapenemase genes in the same bacterial strains was reported for 
the first time in Klebsiella spp. collected from October 2006 to November 2007 by the Emory 
University Hospital Microbiology Laboratory, Atlanta, GA, USA [16]. In this study, authors 
reported the presence of an ESBL in 19 of 26 (73%) of the KPC isolates [16]. Knowing the 
technical challenges in identifying ESBL and carbapenemase genes among resistant bacterial 
strains [17], it is difficult to affirm the absence of these genes before its first description. 
The emergence of multidrug-resistant (MDR) GNB and the lack of new antimicrobial agents 
occurred concurrently with a resurgence of interest in colistin use in human medicine starting in 
the late 1990s [10].  
The first identification of a co-localization of mcr-1 and ESBL genes on a unique plasmid dates 
back to 2005 [6]. From 2006 to 2014, Haenni and collaborators reported an increase of the 
proportion of mcr-1 genes among ESBL-producing E. coli in French calves, from 4.76% to 
21.28% in 2006 and 2014 respectively [8]. In these two old bacterial collections, the mcr-1 gene 
was detected in ESBL producing isolates likely because these previously identified ESBL isolates 
or sequences were available in the laboratories, which was not the case for non-ESBL isolates [6, 
8]. This may have resulted in the preferential detection of the mcr-1 gene in these identified 
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ESBL isolates; non-ESBL isolates in existence could not be tested because they were not 
available in laboratories [7]. The oldest collection of E. coli strains harboring the mcr-1 gene was 
collected in China between 1970 and 2014, however we have no information if these isolates are 
ESBL producing bacteria or not [9].  
The prevalence of the mcr-1 gene among ESBL producing isolates from farm animals was not 
statistically higher than that found in ESBL-positive E coli isolates from humans [7, 18]. In 2009, 
the New Delhi metallo-beta-lactamase-1 (NDM-1) was discovered – a novel broad-spectrum 
carbapenemase with the ability to inactivate all β-lactams except aztreonam and with the 
characteristic of not being inhibited by clavulanic acid [19]. Since 2009, there have been two 
studies, the first carried out in China [9] and the second in Japan [20], that have both reported a 
significant increase in mcr-1 gene prevalence in E. coli strains obtained from food animals. This 
finding was explained by the increased use of colistin in animal production in these two countries 
over the last few years. The sudden and permanent increase of the mcr-1 gene over time presents 
a striking similarity to the increase in the numbers of β-lactamase enzymes identified globally, as 
previously presented by Davies [21]. More recently, two E. coli strains harboring mcr-1 and 
carbapenemase genes were isolated from the urine samples of two patients in the United States. 
The first strain was harboring mcr-1 and blaCTX-M genes [22] and the second strain was harboring 
mcr-1 and blaNDM-5 genes [23]. In China, two E. coli strains coproducing MCR-1 and NDM-1, 
were recovered from two patients with bloodstream infections [24]. MCR-1 producing E. coli 
coproducing either ESBL, AmpC (CMY-2) cephalosporinase, or NDM-9 enzymes were also 
isolated from chicken meat [7, 25]. However, in the absence of therapeutic historical data in these 
studies, it is difficult to determine whether β-lactam or colistin use had greater involvement in the 
exacerbation of ESBL and carbapenemase enzyme spread. Interestingly, Haenni and 
collaborators showed an increasing prevalence of the mcr-1 gene in ESBL isolates from French 
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calves in spite of a decrease in colistin use in animal husbandry in France [8]. Likewise in Brazil, 
the mcr-1 gene was identified at a prevalence of 3 % in E. coli strains in poultry that had not been 
exposed to polymyxin at any point in their lives (around 40 days) [26]. 
Moreover, in countries where colistin is not approved for veterinary use, such as the United 
States, it is difficult to accuse animal productions of being responsible for colistin resistance 
transfer to humans. Even in Europe, studies could not confirm a causal link between animals and 
humans regarding colistin resistance transfer [7].  
Some studies reported that the prevalence of the mcr-1 gene is more significant in ESBL positive 
isolates compared to non-ESBL ones [8]. However, given that the identification of ESBL and/or 
carbapenemase genes in bacteria harboring the mcr-1 gene was not performed in over 50% of the 
scientific studies [27], it is difficult to establish a link between ESBL positive or negative isolates 
and the prevalence of the mcr-1 gene identified worldwide. Several studies have reported that the 
prevalence of the mcr-1 gene was more significant in ESBL positive isolates compared to 
carbapenemase positive ones [27, 28]. 
We believe that a historical link has existed between mcr-1, ESBL, and carbapenemase genes 
since the 1980s, however this historical evidence requires confirmation through the identification 
of the mcr-1 gene present in several old collections of ESBL-positive strains to trace the kinetics 
over time between ESBL, carbapenemase, and mcr-1 genes.  
It is reasonable to consider that the use of broad-spectrum cephalosporins or other β-lactam 
antibiotics in either veterinary or human medicine may have led to colistin resistance. This fact 
might explain the identification of the mcr-1 gene in patients in countries where colistin is not 
approved for farm animals, such as the United States. Moreover, some studies raised the 
possibility of acquiring ESBL, carbapenemase, and mcr-1 genes following a stay in endemic 
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countries and a subsequent human transmission of these genes [29], which might be the case in 
the United States and others countries. 
The re-evaluation of colistin use in livestock, as initiated by several regulatory agencies such as 
the European Medicines Agency (EMA), needs an overall approach that includes not only 
colistin use reduction but also the reduction of all antibiotic use, especially those of critical 
importance for human health. 
 
 
Fig. 1. Schematic illustration of some historical events that combine ESBL and 
carbapenemase enzyme identification with colistin resistance mcr-1 gene emergence. ESBL: 
Extended-Spectrum β-Lactamases. KPC-1: Klebsiella pneumoniae carbapenemase-1. GNB: 
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Gram-negative bacteria. NDM-1: New Delhi metallo-beta-lactamase-1. WHO: World Health 
Organization. Dashed lines indicate a retrospective study. 
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